CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

RealTime Software Solutions Acquires Complion

RealTime Software Solutions Acquires...

What role does artificial intelligence play in the employment process?

What role does artificial...

Why AI is Used for Quality Management in Life Science

Why AI is Used for Quality Management...

Application of AI in Genetics

Application of AI in Genetics

How Artificial Intelligence Impacts Biotechnology

How Artificial Intelligence Impacts...

Akanta's Contextual Intelligence 360 to Enhance Customer Experience

Akanta's Contextual Intelligence 360...

MMIT/Evaluate to Boost Pharma Analytics After Acquisition of Panalgo

MMIT/Evaluate to Boost Pharma...

Syneos Health's Acquisition of RxDataScience to Help Boost Product Development

Syneos Health's Acquisition of...

RealTime Software Solutions Acquires Complion

RealTime Software Solutions Acquires...

What role does artificial intelligence play in the employment process?

What role does artificial...

Why AI is Used for Quality Management in Life Science

Why AI is Used for Quality Management...

Application of AI in Genetics

Application of AI in Genetics

How Artificial Intelligence Impacts Biotechnology

How Artificial Intelligence Impacts...

Akanta's Contextual Intelligence 360 to Enhance Customer Experience

Akanta's Contextual Intelligence 360...

MMIT/Evaluate to Boost Pharma Analytics After Acquisition of Panalgo

MMIT/Evaluate to Boost Pharma...

Syneos Health's Acquisition of RxDataScience to Help Boost Product Development

Syneos Health's Acquisition of...

Eyenuk Receives US$6.2 Million in Financing Round

Life Sciences Review Life Sciences Review | Thursday, July 29, 2021
Tweet

Eyenuk announced that it had finished a US$6.2 million financing round led by AXA IM through AXA IM Alts.


FREMONT, CA: Eyenuk, Inc., an international artificial intelligence (AI) medical technology and services organization and the pioneer in real-world AI Eye Screening applications, recently announced that it had completed a US$6.2 million financing round led by AXA IM through AXA IM Alts, a worldwide leader in alternative investments with c. 162 billion in assets under management. Existing Eyenuk investors were also involved in the round.


Eyenuk will use the funds to speed up the commercialization of the EyeArt AI System, which was approved by the FDA in 2020 and is being reimbursed by Medicare and other payors.


“AXA IM Alts investment in Eyenuk is advised by Dr. Zina Affas Besse, Managing Partner at Global Health Investment Advisors (GHIA), a pioneer in impact investing in life science companies. We are very impressed with all that the Eyenuk team has accomplished to date,” said Dr. Affas Besse. “We look forward to supporting the company as it accelerates global commercialization and pipeline development programs.”


“We are excited about Eyenuks business potential as evidenced by Eyenuks impressive business and clinical accomplishments to-date,” said Jonathan Dean, Head of Impact Investing at AXA IM Alts. “We are proud to invest in some of the most innovative technologies that address major public health issues worldwide, while searching to generate attractive social and financial returns. Eyenuks innovative healthcare AI technologies aim to deliver tangible impact around the world alongside attractive financial returns.”


“We are thrilled to welcome new institutional investors to the Eyenukteam,” said Kaushal Solanki, Ph.D., Founder, and CEO of Eyenuk. “We look forward to working with AXA IM Alts and other investors, who share Eyenuks vision of creating globally accessible AI platform technology that can enable drastic reduction of preventable blindness across the world.”


To support its long-term growth and innovation initiatives, Eyenuk aims to close a larger financing round in late 2021.


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/eyenuk-receives-us62-million-in-financing-round-nwid-475.html